H.C. Wainwright Maintains Enlivex Therapeutics(ENLV.US) With Buy Rating, Maintains Target Price $6
H.C. Wainwright Maintains Enlivex Therapeutics(ENLV.US) With Buy Rating, Maintains Target Price $6
Enlivex Therapeutics Price Target Announced at $13.00/Share by EF Hutton
Enlivex Therapeutics Analyst Ratings
Enlivex Therapeutics Analyst Ratings
Enlivex Therapeutics Analyst Ratings
Enlivex Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $15 Price Target
Enlivex Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $15 Price Target
Enlivex Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $15 Price Target
H.C. Wainwright Sticks to Its Buy Rating for Enlivex Therapeutics (ENLV)
H.C. Wainwright Keeps Their Buy Rating on Enlivex Therapeutics (ENLV)
H.C. Wainwright Reaffirms Their Buy Rating on Enlivex Therapeutics (ENLV)
Enlivex Therapeutics (ENLV) Receives a Buy From H.C. Wainwright
H.C. Wainwright Keeps a Buy Rating on Enlivex Therapeutics (ENLV)
No Data
No Data